Firms

Newton Biocapital

Newton Biocapital

Brussels, Belgium · Tokyo, Japan

newtonbiocapital.com

Newton Biocapital is a Belgian life-sciences venture-capital platform established in2017 by Alain Parthoens and Goro Takeda, with offices in Brussels and Tokyo. It invests in research, preclinical and clinical companies developing treatments for chronic conditions, using scientific, medical and regulatory expertise and board involvement to advance portfolio programmes and connect the European and Japanese ecosystems. Its disclosed portfolio includes neuroscience businesses Synergia Medical and NeuVasQ Biotechnologies, as well as RNA therapeutics, small-molecule discovery, antibodies and medical devices. The investor brand is distinguished from its legal managers and subscribing funds: Newton Biocapital Partners SRL BE0673.852.565, incorporatedApril4,2017 and registered with FSMA as a small AIF manager sinceMay9,2017, manages Newton Biocapital I SA BE0674.831.275, incorporatedApril25,2017; Newton Biocapital II Partners SRL BE0767.828.541 is a distinct related legal manager, registered sinceJanuary25,2022, for Newton Biocapital II SA BE0779.335.513, incorporatedDecember24,2021. These are qualified under the shared platform record without claiming that the two legal managers or funds are identical subscribers. The unrelated existing Newton Fund investor is preserved and not merged. Fund I closed fundraising atEUR114M according to its ownAugust27,2020 J-Pharma investment release, with the exact final closing day unpublished; the current website continues to report114M while current statutory subscribedcapital is a separate110.85035949M figure. Fund II announced aEUR50M initial commitment closing onFebruary15,2022, with a150M fundraising target that is not recorded as actual capital. The current own fund page reports53M fund size, and current registry subscribedcapital53.112011M is separately qualified; no final closing date, paid drawdown or extra50M+53M fund is inferred. The current public directory publishes nine operating investment/regulatory/support professionals and four independent-director or emeritus affiliations, plus the historical co-founder Goro Takeda, who died inDecember2018. All14 directory people have genuine original employer portraits. Three further statutory fund representatives bring the combined public operating/governance roster to17 unique people, not an employee headcount. Pierre Detrixhe and François Fontaine reuse existing authentic biographies, images and issuer roles. Statutory-only Sophie Sauvage and Peter Seiler have no independently matched authentic portrait. Legal-name differences Guy/Guillaume Heynen are qualified rather than assumed; no duplicate alias or invented personal investment is created. The platform’s native issuer links are owned by the separate company audits: Synergia’s2018 lead and2022 follow-on, and NeuVasQ’s2021 SeriesA through Fund I. Portfolio mentions do not imply a new cash round, every subsequent financing, or approval of an investigational therapy.

Founded
2017
Type
Venture capital

Funds2

  • Newton Biocapital I (Belgian private pricaf SA)€114M

    Actual legal fund BE0674.831.275, initiated2017 and managed by Newton Biocapital PartnersSRL BE0673.852.565. OwnAugust27,2020 issuer-distributed press release explicitly says fundraising had already closed atEUR114M; exact final closingday unknown, announcedAtNULL. Current ownsite repeats114M; current statutory subscribedcapital110.85035949M is a distinct legalcapital snapshot, not newLPcash. No duplicate114Mfinal raise/event. FundI no longer solicits new investors or seeks new portfoliocompanies perownSFDR.

  • Newton Biocapital II (Belgian private pricaf SA)€53M

    Actual legal fund BE0779.335.513, incorporatedDecember24,2021 andmanagedbydistinct Newton Biocapital IIPartnersSRL BE0767.828.541. Current ownfundpage explicitlyreportsEUR53M size; exact last/final closingday unpublished, announcedAtNULL. InitialEUR50MclosedcommitmentsannouncedFebruary15,2022 werewithinthissamefund, notaddedasanother50Mpooledraise.150Mwasfundraisingtarget, notactualcapital. CurrentKBO53.112011Msubscribedcapital sourcequalified separatelyfromroundedfundsize andactualpaidcompanytickets. Own2025ESGreport datedJune23,2026 nameslegalfundandmanager.

Team

Operations and support

Ajit ShettyAjit ShettyChairman of the Board of NBC I and NBC II
Alain ParthoensAlain ParthoensChief Executive Officer · Co-founder
Daisuke MorishitaDaisuke MorishitaVenture Partner
Danny GonnissenDanny GonnissenChief Operating Officer
Dario PadovaniDario PadovaniChief Financial Officer
Dirk BoogmansDirk BoogmansVice-Chairman and Chairman of the Audit Committee of NBC I and NBC II
François FontaineFrançois FontaineStatutory Permanent Representative — Fund I · Statutory Permanent Representative — Fund II
Goro TakedaGoro TakedaCo-founder (historical; deceased December2018)
Guy HeynenGuy HeynenChief Medical and Regulatory Officer
Jean CombalbertJean CombalbertIndependent Director
Jean-Claude DeschampsJean-Claude DeschampsChairman Emeritus and Advisor to the Board of NBC I and NBC II
Michihiko WadaMichihiko WadaChief Regulatory and Development Officer
Peter SeilerStatutory Permanent Representative — Fund II
Pierre DetrixhePierre DetrixheVenture Director
Sadashi SuzukiSadashi SuzukiJapan Representative
Sophie SauvageSophie SauvageStatutory Permanent Representative — Fund I · Statutory Permanent Representative — Fund II
Toko SennaToko SennaAssistant to the CEO / Office Manager / (Brussels Office)

Co-investing

ORSA Fund
SFPIM
Wallonie Entreprendre
Karista
A & B (HK) Company Limited

Investments

¥1.74B2020-08-27J-PharmaNewton Biocapital
$—2025-12-10BioxodesNewton Biocapital
$—2025-03-24Augustine TherapeuticsNovo Holdings, Jeito Capital, AdBio Partners, PMV (Participatiemaatschappij Vlaanderen), Gemma Frisius Fund, Asabys Partners, Newton Biocapital, V-Bio Ventures, Eli Lilly and Company, CMT Research Foundation, VIB (Flanders Institute for Biotechnology)
€9M2022-09-12Synergia MedicalSFPIM, Newton Biocapital, ORSA Fund, Wallonie Entreprendre, TCD Capital
€20M2021-06-22Neuvasq BiotechnologiesNewton Biocapital, SFPIM, ORSA Fund, Wallonie Entreprendre, Theodorus IV, Sambrinvest
€8M2018-02-19Synergia MedicalNewton Biocapital, SFPIM, ORSA Fund, Wallonie Entreprendre
€6MUnknown dateActicor BiotechGO Capital, Newton Biocapital, Karista, Anaxago
€14MUnknown dateActicor BiotechNewton Biocapital, Karista, CMS Medical Venture Investment (HK) Limited, A & B (HK) Company Limited, Mirae Asset Capital